XORTX Announces US$5 Million Public Offering
Original article ↗ 🔒 Paywalled source — limited preview availableB.I.A.S. ANALYSIS
CENTER LEFT
LEFTCENTERRIGHT
Signal breakdown
Heuristic (v1/v3)
-1.00 · LEFT
ML v2 (DistilBERT)
0.000 · CENTER
Ensemble
-0.500 · CENTER LEFT
🏦 Source Intelligence
Rolling outlet bias
CENTER
avg -0.045
2,788 articles tracked
7-day bias trend
LcenterR
Article Excerpt
CALGARY, Alberta, May 14, 2026 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces the pricing of a public offering of 2,659,574 common shares (“Common Shares”) or common shares...
Read full article at Montreal Gazette ↗
How we scored this article
WTF uses a two-tier system: every article gets a heuristic bias score from keyword analysis, and priority articles (high overlap across 3+ outlets or strong heuristic signal) get full LLM analysis from B.I.A.S. and V.E.R.I.F.Y.
Analyzed by
B.I.A.S.
V.E.R.I.F.Y.
L.O.C.A.L.
pending
May 14, 2026
📰
🔒 Unlock — Starter+
1 outlet covered this story
Side-by-side comparison · bias by outlet · framing analysis